Boehringer Ingelheim’s Spiriva Respimat tiotropium soft mist inhaler has now been approved by the FDA for the treatment of asthma in patients 12 years old and older. Spiriva Respimat was approved for the treatment of COPD in the US in September 2014, and it is currently approved for the treatment of asthma in over 50 countries.
Boehringer Ingelheim Head of Respiratory Medicine William Mezzanotte commented, “The US FDA approval of Spiriva Respimat in asthma establishes a new class of inhaled asthma therapy and provides an efficacious, new option for patients. There is extensive clinical evidence demonstrating that Spiriva Respimat can improve outcomes for patients with asthma who remain symptomatic despite the use of ICS/LABA maintenance therapy. This is reflected by the inclusion of Spiriva Respimat in the latest update of the GINA global asthma management strategy.”
Read the Boehringer Ingelheim press release.